Substance-use simulation impairs driving capability in patients with cirrhosis regardless of hepatic encephalopathy - Acharya C, McGeorge S, Fagan A, Wade JB, Lee H, Luketic V, Sterling RK, Thacker L, Bajaj JS.
Driving is independently affected by cirrhosis and hepatic encephalopathy (HE) and alcohol/substance use, but their concomitant impact is unclear. We aimed to determine the impact of alcohol and other substances on driving-simulator performance in cirrhosi... (Source: SafetyLit)
Source: SafetyLit - July 19, 2022 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Roche launches innovative dual antigen and antibody diagnostic test supporting the fight to eliminate the hepatitis C virus
Elecsys HCV Duo is the first commercially available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status.TheElecsys HCVDuo immunoassay enables significantly earlier diagnosis of active HCV infection, making it possible to get patients appropriate care sooner to stop both the disease progression and transmission.Basel, 18 July 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the Elecsys ® HCV Duo immunoassay in countries that accept the CE Mark. Elecsys HCV Duo is the first available immunoassay that allows the simultaneous ...
Source: Roche Investor Update - July 18, 2022 Category: Pharmaceuticals Source Type: news
Roche launches innovative dual antigen and antibody diagnostic test supporting the fight to eliminate the hepatitis C virus
Elecsys HCV Duo is the first commercially available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status.TheElecsys HCVDuo immunoassay enables significantly earlier diagnosis of active HCV infection, making it possible to get patients appropriate care sooner to stop both the disease progression and transmission.Basel, 18 July 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the Elecsys ® HCV Duo immunoassay in countries that accept the CE Mark. Elecsys HCV Duo is the first available immunoassay that allows the simultaneous ...
Source: Roche Media News - July 18, 2022 Category: Pharmaceuticals Source Type: news
Liver Cancer Risk Persists After DAA Treatment for HCV Liver Cancer Risk Persists After DAA Treatment for HCV
Patients with cirrhosis and those with high fibrosis-4 scores face the highest risks and should continue to be screened.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - July 14, 2022 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Fatty liver disease symptoms: The sign in your vomit that indicates cirrhosis - see a GP
FATTY liver disease is caused by a build-up of fat in the liver. Although in its early stages it often does not cause any harm, it can lead to serious health problems if it develops. Cirrhosis is one such problem and is the most severe stage of the disease. (Source: Daily Express - Health)
Source: Daily Express - Health - July 13, 2022 Category: Consumer Health News Source Type: news
HCV Eradication in HCC and Decreased Hepatic Functional Reserve HCV Eradication in HCC and Decreased Hepatic Functional Reserve
Does DAA therapy after hepatocellular carcinoma treatment benefit patients with advanced-stage HCC or HCC with decompensated cirrhosis?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 12, 2022 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
High Residual Liver Cancer Risk in HCV-Cured Cirrhosis High Residual Liver Cancer Risk in HCV-Cured Cirrhosis
Patients with cirrhosis cured of hepatitis C have a 410 times greater risk of hepatocellular carcinoma than the general population and need regular screening, researchers say.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 11, 2022 Category: Consumer Health News Tags: Gastroenterology News Source Type: news
Bulevirtide Reduces Hepatitis D Viral Load Bulevirtide Reduces Hepatitis D Viral Load
Data from an ongoing study in patients with compensated cirrhosis and clinically significant portal hypertension have raised hope for an emerging treatment option in this rare, deadly disease.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - July 6, 2022 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Jaundice, Malaise in Woman With Heroin Habit, Inactive Hepatitis B
(MedPage Today) -- HDV diagnosis portends imminent cirrhosis despite initial resolution of symptoms (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - July 5, 2022 Category: Gastroenterology Source Type: news
HF May Not Be Causal Factor in Hepatorenal Syndrome With AKI HF May Not Be Causal Factor in Hepatorenal Syndrome With AKI
A new study sheds light on the hemodynamic changes that accompany the progression of cirrhosis and suggests that cardiac dysfunction might not be a causal factor in hepatorenal syndrome with AKI.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - July 1, 2022 Category: Radiology Tags: Cardiology News Source Type: news
Mixed Bag for Semaglutide in NASH-Related Compensated Cirrhosis
(MedPage Today) -- Although semaglutide (Ozempic) missed its mark in improving liver fibrosis for patients with nonalcoholic steatohepatitis (NASH)-related cirrhosis, improvements were noted in cardiometabolic parameters and other biomarkers, according... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - June 27, 2022 Category: Endocrinology Source Type: news
Are Pain Meds the Only Option for Chronic Pain in Cirrhosis? Are Pain Meds the Only Option for Chronic Pain in Cirrhosis?
The first treatment option for any pain should be self-directed, nonpharmacologic interventions.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 27, 2022 Category: Consumer Health News Tags: Internal Medicine News Source Type: news
Fatty liver disease symptoms: The signs liver scarring is 'blocking liver function'
LIVER disease comes in two main forms. Non-alcoholic fatty liver disease is the term for a range of conditions caused by a build-up of fat in the liver. You can also get alcohol-related liver disease, which is liver damage that is caused by drinking too much alcohol. The NHS says cirrhosis is "the most severe stage" of NAFLD occurring after years of inflammation. (Source: Daily Express - Health)
Source: Daily Express - Health - June 27, 2022 Category: Consumer Health News Source Type: news
Liver Cirrhosis Tied to Elevated Risk for Stroke
(MedPage Today) -- Liver cirrhosis was linked to a greater risk for stroke in a large retrospective study, and the association was independent of established cardiovascular risk factors, a research reported.
In the study of nearly 1.3 million... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 26, 2022 Category: Cardiology Source Type: news
Alarming Increase Seen in U.S. Deaths From Alcoholic Cirrhosis
Mortality rate increased more than threefold between 1999 and 2019 (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - June 23, 2022 Category: Psychiatry Tags: Family Medicine, Gastroenterology, Internal Medicine, Psychiatry, Journal, Source Type: news
